Logo image
Erythropoietin protects outer blood-retinal barrier in experimental diabetic retinopathy by up-regulating ZO-1 and occludin
Journal article   Peer reviewed

Erythropoietin protects outer blood-retinal barrier in experimental diabetic retinopathy by up-regulating ZO-1 and occludin

Chaoyang Zhang, Hai Xie, Qian Yang, Yiting Yang, Weiye Li, Haibin Tian, Lixia Lu, Fang Wang, Jing-Ying Xu, Furong Gao, …
Clinical & experimental ophthalmology, v 47(9), pp 1182-1197
Dec 2019
PMID: 31483932

Abstract

Animals Blood-Retinal Barrier - drug effects Blotting, Western Diabetes Mellitus, Experimental Diabetic Retinopathy - drug therapy Diabetic Retinopathy - metabolism Diabetic Retinopathy - physiopathology Erythropoietin - administration & dosage Intravitreal Injections Male Occludin - metabolism Rats Rats, Sprague-Dawley Recombinant Proteins - administration & dosage Retinal Vessels - drug effects Retinal Vessels - physiopathology Up-Regulation Zonula Occludens-1 Protein - metabolism
To explore the mechanisms of erythropoietin (EPO) in maintaining outer blood-retinal barrier (BRB) in diabetic rats. Sprague-Dawley rats were rendered diabetic with intraperitoneal injection of streptozotocin, and then followed by intravitreal injection of EPO. Two and four weeks later, the permeability of outer BRB was examined with FITC-dextran leakage assay, following a method to demarcate the inner and outer retina based on retinal blood supply. The glyoxal-treated ARPE-19 cells, incubated with EPO, soluble EPO receptor (sEPOR), Gö6976, or digoxin, were studied for cell viability and barrier function. The expressions of ZO-1, occludin, VEGFR2, HIF-1α, MAPKs, and AKT were examined with Western blot and immunofluorescence. The major Leakage of FITC-dextran was detected in the outer nuclear layer in both 2- and 4-week diabetic rats. The leakage was largely ameliorated in EPO-treated diabetic rats. The protein expressions of ZO-1 and occludin in the RPE-Bruch's membrane choriocapillaris complex were significantly decreased, whereas HIF-1α and JNK pathways were activated, in 4-week diabetic rats. These changes were prevented by EPO treatment. The in vitro study with ARPE-19 cells confirmed these changes, and the protective effect of EPO was abolished by sEPOR. Gö6976 and digoxin rescued the tight junction and barrier function in glyoxal-treated ARPE-19 cells. In early diabetic rats, the outer BRB might be more severely damaged and its breakdown is the major factor for retinal oedema. EPO maintains the outer BRB integrity through down-regulation of HIF-1α and JNK signallings, and thus up-regulating ZO-1 and occludin expressions in RPE cells.

Metrics

8 Record Views
56 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Ophthalmology
Logo image